Primary ex vivo CLL cultures used in this study
| Patient ID . | Sex/age, y . | Stage, Binet . | Ig produced . | IGHV (CDR3 subset)* . |
|---|---|---|---|---|
| p239 | M/74 | A | IgM | IGHV1-69UM (subset 6) |
| p241 | M/63 | C | IgM | IGHV3-21UM |
| p457 | M/57 | B | IgM | IGHV1-18UM (subset 1) |
| p467 | F/61 | A | IgG | IGHV4-34M |
| p497 | M/73 | C | IgM | IGHV1-2UM (subset 1) |
| p498 | M/62 | B | IgM | IGHV3-49UM |
| p524 | M/68 | C | IgM | IGHV3-11UM (subset 61) |
| p571 | M/58 | A | IgG | IGHV4-4M |
| p781 | F/58 | B | IgM | IGHV3-11UM (subset 61) |
| p814 | M/68 | C | IgM | IGHV3-66UM |
| p825 | F/71 | B | IgM | IGHV3-73UM |
| ID-5 | F/66 | A | IgG | IGHV3-33M |
| ID-6 | M/65 | C | IgM | IGHV1-69UM |
| ID-7 | F/54 | B | IgM | IGHV1-69UM (subset 6) |
| ID-11 | M/56 | C | IgM | IGHV3-21UM (subset 2) |
| ID-13 | M/70 | A | IgM | ND |
| ID-15 | M/50 | C | IgM | IGHV3-20UM |
| ID-20 | M/78 | B | IgM | IGHV4-34M |
| ID-23 | M/75 | C | IgM | IGHV3-21M (subset 2)‡ |
| p417† | M/69 | A | — | IGHV4-30UM |
| p432† | M/58 | A | — | IGHV1-69UM |
| p494† | M/71 | C | — | IGHV3-48UM (subset 23) |
| p562† | F/61 | A | — | IGHV4-59M |
| Patient ID . | Sex/age, y . | Stage, Binet . | Ig produced . | IGHV (CDR3 subset)* . |
|---|---|---|---|---|
| p239 | M/74 | A | IgM | IGHV1-69UM (subset 6) |
| p241 | M/63 | C | IgM | IGHV3-21UM |
| p457 | M/57 | B | IgM | IGHV1-18UM (subset 1) |
| p467 | F/61 | A | IgG | IGHV4-34M |
| p497 | M/73 | C | IgM | IGHV1-2UM (subset 1) |
| p498 | M/62 | B | IgM | IGHV3-49UM |
| p524 | M/68 | C | IgM | IGHV3-11UM (subset 61) |
| p571 | M/58 | A | IgG | IGHV4-4M |
| p781 | F/58 | B | IgM | IGHV3-11UM (subset 61) |
| p814 | M/68 | C | IgM | IGHV3-66UM |
| p825 | F/71 | B | IgM | IGHV3-73UM |
| ID-5 | F/66 | A | IgG | IGHV3-33M |
| ID-6 | M/65 | C | IgM | IGHV1-69UM |
| ID-7 | F/54 | B | IgM | IGHV1-69UM (subset 6) |
| ID-11 | M/56 | C | IgM | IGHV3-21UM (subset 2) |
| ID-13 | M/70 | A | IgM | ND |
| ID-15 | M/50 | C | IgM | IGHV3-20UM |
| ID-20 | M/78 | B | IgM | IGHV4-34M |
| ID-23 | M/75 | C | IgM | IGHV3-21M (subset 2)‡ |
| p417† | M/69 | A | — | IGHV4-30UM |
| p432† | M/58 | A | — | IGHV1-69UM |
| p494† | M/71 | C | — | IGHV3-48UM (subset 23) |
| p562† | F/61 | A | — | IGHV4-59M |
All patients were untreated at time of blood sampling.
M indicates mutated CLL; UM, unmutated CLL; ND, not determined; and — not applicable.
For more detailed information see Table S2; Tobin et al14 ; and Murray et al.8
Cells from these patients were included only in the vimentin analysis (Figure 4C).
ID-23 has a 9-codon–long CDR3, but with IGHJ3 usage.